{"groups":[{"description":"Study Drugs Arimidex (Anastrozole), Zometa (Zoledronate; zoledronic acid)\n\nanastrozole: 1 mg/d\n\nzoledronic acid: 4 mg q6m\n\ngoserelin: 3.6 mg goserelin subcutaneously every 28 days","id":"FG000","title":"AZ (Arimidex+Zoledronate)"},{"description":"Study Drugs Nolvadex (Tamoxifen), Zometa (Zoledronate; zoledronic acid)\n\ntamoxifen: 20 mg/d\n\nzoledronic acid: 4 mg q6m\n\ngoserelin: 3.6 mg goserelin subcutaneously every 28 days","id":"FG001","title":"TZ (Tamoxifen+Zoledronate)"},{"description":"Study Drug Arimidex (Anastrozole)\n\nanastrozole: 1 mg/d\n\ngoserelin: 3.6 mg goserelin subcutaneously every 28 days","id":"FG002","title":"AC (Arimidex Control)"},{"description":"Study Drug Nolvadex (Tamoxifen)\n\ntamoxifen: 20 mg/d\n\ngoserelin: 3.6 mg goserelin subcutaneously every 28 days","id":"FG003","title":"TC (Tamoxifen Control)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"20"},{"groupId":"FG002","numSubjects":"20"},{"groupId":"FG003","numSubjects":"18"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"14"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"5"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"18"},{"groupId":"FG003","numSubjects":"8"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"450"},{"groupId":"FG001","numSubjects":"450"},{"groupId":"FG002","numSubjects":"453"},{"groupId":"FG003","numSubjects":"450"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"415"},{"groupId":"FG001","numSubjects":"409"},{"groupId":"FG002","numSubjects":"403"},{"groupId":"FG003","numSubjects":"405"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"41"},{"groupId":"FG002","numSubjects":"50"},{"groupId":"FG003","numSubjects":"45"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The first patient was randomized June 17, 1999, the last patient was randomized May 17, 2006. Randomization took place in 66 Austrian and 10 German clinical sites. In total, 1.803 patients were enrolled."}